Format
Sort by

Send to

Choose Destination

Search results

Items: 1 to 20 of 120

1.

Chronic kidney disease, cerebral blood flow, and white matter volume in hypertensive adults.

Kurella Tamura M, Pajewski NM, Bryan RN, Weiner DE, Diamond M, Van Buren P, Taylor A, Beddhu S, Rosendorff C, Jahanian H, Zaharchuk G; SPRINT Study Research Group.

Neurology. 2016 Mar 29;86(13):1208-16. doi: 10.1212/WNL.0000000000002527. Epub 2016 Feb 26.

PMID:
26920359
2.

A Miniature Protein Stabilized by a Cation-π Interaction Network.

Craven TW, Cho MK, Traaseth NJ, Bonneau R, Kirshenbaum K.

J Am Chem Soc. 2016 Feb 10;138(5):1543-50. doi: 10.1021/jacs.5b10285. Epub 2016 Jan 26.

PMID:
26812069
3.

A Randomized Trial of Intensive versus Standard Blood-Pressure Control.

SPRINT Research Group, Wright JT Jr, Williamson JD, Whelton PK, Snyder JK, Sink KM, Rocco MV, Reboussin DM, Rahman M, Oparil S, Lewis CE, Kimmel PL, Johnson KC, Goff DC Jr, Fine LJ, Cutler JA, Cushman WC, Cheung AK, Ambrosius WT.

N Engl J Med. 2015 Nov 26;373(22):2103-16. doi: 10.1056/NEJMoa1511939. Epub 2015 Nov 9.

4.

Baseline characteristics of African Americans in the Systolic Blood Pressure Intervention Trial.

Still CH, Craven TE, Freedman BI, Van Buren PN, Sink KM, Killeen AA, Bates JT, Bee A, Contreras G, Oparil S, Pedley CM, Wall BM, White S, Woods DM, Rodriguez CJ, Wright JT Jr; SPRINT Study Research Group.

J Am Soc Hypertens. 2015 Sep;9(9):670-9. doi: 10.1016/j.jash.2015.06.012. Epub 2015 Aug 7.

PMID:
26320890
5.

Increased prevalence of preeclampsia among women undergoing procedural intervention for renal artery fibromuscular dysplasia.

Vance CJ, Taylor RN, Craven TE, Edwards MS, Corriere MA.

Ann Vasc Surg. 2015 Aug;29(6):1105-10. doi: 10.1016/j.avsg.2015.03.037. Epub 2015 May 22.

PMID:
26004957
6.

Change in estimated glomerular filtration rate and fracture risk in the Action to Control Cardiovascular Risk in Diabetes Trial.

Isakova T, Craven TE, Scialla JJ, Nickolas TL, Schnall A, Barzilay J, Schwartz AV; Action to Control Cardiovascular Risk in Diabetes (ACCORD) Trial.

Bone. 2015 Sep;78:23-7. doi: 10.1016/j.bone.2015.04.037. Epub 2015 Apr 30.

PMID:
25937184
7.

Systolic Blood Pressure Control Among Individuals With Type 2 Diabetes: A Comparative Effectiveness Analysis of Three Interventions.

Espeland MA, Probstfield J, Hire D, Redmon JB, Evans GW, Coday M, Lewis CE, Johnson KC, Wilmoth S, Bahnson J, Dulin MF, Green JB, Knowler WC, Kitabchi A, Murillo AL, Osei K, Rehman SU, Cushman WC; Look AHEAD Research Group; ACCORD Study Group.

Am J Hypertens. 2015 Aug;28(8):995-1009. doi: 10.1093/ajh/hpu292. Epub 2015 Feb 9.

PMID:
25666468
8.

Fibroblast growth factor 23 and incident CKD in type 2 diabetes.

Isakova T, Craven TE, Lee J, Scialla JJ, Xie H, Wahl P, Marcovina SM, Byington RP, Wolf M.

Clin J Am Soc Nephrol. 2015 Jan 7;10(1):29-38. doi: 10.2215/CJN.06190614. Epub 2014 Oct 24.

9.

Intrinsic bioconjugation for site-specific protein PEGylation at N-terminal serine.

Levine PM, Craven TW, Bonneau R, Kirshenbaum K.

Chem Commun (Camb). 2014 Jul 4;50(52):6909-12. doi: 10.1039/c4cc01928h.

PMID:
24840103
10.

A rotamer library to enable modeling and design of peptoid foldamers.

Renfrew PD, Craven TW, Butterfoss GL, Kirshenbaum K, Bonneau R.

J Am Chem Soc. 2014 Jun 18;136(24):8772-82. doi: 10.1021/ja503776z. Epub 2014 Jun 9.

11.

Influence of computed tomography angiography reconstruction software on anatomic measurements and endograft component selection for endovascular abdominal aortic aneurysm repair.

Corriere MA, Islam A, Craven TE, Conlee TD, Hurie JB, Edwards MS.

J Vasc Surg. 2014 May;59(5):1224-31.e1-3. doi: 10.1016/j.jvs.2013.11.003. Epub 2014 Jan 16.

12.

Semisynthesis of peptoid-protein hybrids by chemical ligation at serine.

Levine PM, Craven TW, Bonneau R, Kirshenbaum K.

Org Lett. 2014 Jan 17;16(2):512-5. doi: 10.1021/ol4033978. Epub 2014 Jan 3.

PMID:
24393000
13.

Adding diverse noncanonical backbones to rosetta: enabling peptidomimetic design.

Drew K, Renfrew PD, Craven TW, Butterfoss GL, Chou FC, Lyskov S, Bullock BN, Watkins A, Labonte JW, Pacella M, Kilambi KP, Leaver-Fay A, Kuhlman B, Gray JJ, Bradley P, Kirshenbaum K, Arora PS, Das R, Bonneau R.

PLoS One. 2013 Jul 15;8(7):e67051. doi: 10.1371/journal.pone.0067051. Print 2013.

14.

Chemoselective fragment condensation between peptide and peptidomimetic oligomers.

Levine PM, Craven TW, Bonneau R, Kirshenbaum K.

Org Biomol Chem. 2013 Jul 7;11(25):4142-6. doi: 10.1039/c3ob40606g.

PMID:
23715215
15.

Stent effects on duplex velocity estimates.

Kuppler CS, Christie JW, Newton WB 3rd, Ghanami RJ, Craven TE, Berry JL, Hansen KJ.

J Surg Res. 2013 Jul;183(1):457-61. doi: 10.1016/j.jss.2012.03.004. Epub 2012 Mar 28.

PMID:
23601663
16.

Longitudinal changes in dietary fat intake and associated changes in cardiovascular risk factors in adults with type 2 diabetes: the ACCORD trial.

Kirk JK, Craven T, Lipkin EW, Katula J, Pedley C, O'Connor PJ, Margolis KL.

Diabetes Res Clin Pract. 2013 Apr;100(1):61-8. doi: 10.1016/j.diabres.2013.02.001. Epub 2013 Mar 13.

17.

Determinants of weight gain in the action to control cardiovascular risk in diabetes trial.

Fonseca V, McDuffie R, Calles J, Cohen RM, Feeney P, Feinglos M, Gerstein HC, Ismail-Beigi F, Morgan TM, Pop-Busui R, Riddle MC; ACCORD Study Group.

Diabetes Care. 2013 Aug;36(8):2162-8. doi: 10.2337/dc12-1391. Epub 2013 Feb 14.

18.

Early duplex predicts restenosis after renal artery angioplasty and stenting.

Christie JW, Conlee TD, Craven TE, Hurie JB, Godshall CJ, Edwards MS, Hansen KJ.

J Vasc Surg. 2012 Nov;56(5):1373-80; discussion 1380. doi: 10.1016/j.jvs.2012.05.067.

19.

Fenofibrate-associated changes in renal function and relationship to clinical outcomes among individuals with type 2 diabetes: the Action to Control Cardiovascular Risk in Diabetes (ACCORD) experience.

Bonds DE, Craven TE, Buse J, Crouse JR, Cuddihy R, Elam M, Ginsberg HN, Kirchner K, Marcovina S, Mychaleckyj JC, O'Connor PJ, Sperl-Hillen JA.

Diabetologia. 2012 Jun;55(6):1641-50. doi: 10.1007/s00125-012-2524-2. Epub 2012 Mar 27.

20.

Reversibility of fenofibrate therapy-induced renal function impairment in ACCORD type 2 diabetic participants.

Mychaleckyj JC, Craven T, Nayak U, Buse J, Crouse JR, Elam M, Kirchner K, Lorber D, Marcovina S, Sivitz W, Sperl-Hillen J, Bonds DE, Ginsberg HN.

Diabetes Care. 2012 May;35(5):1008-14. doi: 10.2337/dc11-1811. Epub 2012 Mar 19.

Items per page

Supplemental Content

Loading ...
Write to the Help Desk